| 8.45 0.35 (4.32%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.18 | 1-year : | 12.57 |
| Resists | First : | 9.57 | Second : | 10.77 |
| Pivot price | 8.47  |
|||
| Supports | First : | 7.65 | Second : | 6.36 |
| MAs | MA(5) : | 8.12 |
MA(20) : | 8.62 |
| MA(100) : | 8.59 |
MA(250) : | 5.43 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 22 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 11.6 | Low : | 1.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMMX ] has closed above bottom band by 48.2%. Bollinger Bands are 34.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.65 - 8.69 | 8.69 - 8.73 |
| Low: | 7.94 - 7.98 | 7.98 - 8.03 |
| Close: | 8.37 - 8.45 | 8.45 - 8.52 |
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Fri, 29 May 2026
Immix Biopharma (NASDAQ: IMMX) grants RSUs and stock options to director - Stock Titan
Fri, 29 May 2026
Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78 - Stock Titan
Wed, 27 May 2026
What date does Immix Biopharma's (IMMX) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
Wed, 27 May 2026
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? - Yahoo Finance
Fri, 22 May 2026
Biotech Immix Biopharma pulls in $140.65M from new stock sale - Stock Titan
Fri, 22 May 2026
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 17.5 (%) |
| Held by Institutions | 38.9 (%) |
| Shares Short | 3,220 (K) |
| Shares Short P.Month | 2,960 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39 % |
| Return on Equity (ttm) | -74.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -9.19 |
| PEG Ratio | 0 |
| Price to Book value | 5.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|